UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Recommendations

Info

Presentations A phase 2 study of galunisertib, a novel transforming growth factorbeta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP). Authors*: Sandrine J. Faivre, Armando Santoro, Edward Gane, Robin Kate Kelley, I Ollivier Hourmand, Eric Assenat, Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Michael M. F. Lahn, Eric Raymond, Karim A. Benhadji, Gianluigi Giannelli Abstract #: 4070 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #62 Session: Gastrointestinal (Noncolorectal) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 4070) __________________________________________________________________________ A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (nab-P) plus apatorsen (A) or placebo (Pl) in patients (pts) with metastatic pancreatic cancer (mPC): The RAINIER trial. Authors*: Andrew H. Ko, Patrick Brian Murphy, James D. Peyton, Dianna Shipley, Ahmed Al-Hazzouri, Francisco Antonio Rodriguez, Mark Sanders Womack, Henry Q. Xiong, David Michael Waterhouse, Margaret A. Tempero, Shuangli Guo, Cassie Michelle Lane, Christopher Earwood, Laura M. DeBusk, Johanna C. Bendell Abstract #: 4119 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #111 Poster Session: Gastrointestinal (Noncolorectal) Cancer Citation: J Clin Oncol 34, 2016 (suppl; abstr 4119) Ko Research Interests: My work focuses on gastrointestinal malignancies, where I have developed and led multiple clinical trials, both within UCSF and across multiple sites. I am interested in the development and evaluation of new therapeutic agents ranging from novel cytotoxics to molecular targeted agents to immunotherapies, with a particular emphasis in pancreatic cancer. This work entails collaborating with laboratory-based investigators on translational science to identify individual patient/tumor characteristics that influence prognosis and response to specific therapies. I lead the UCSF site committee for gastrointestinal cancer-specific clinical trial development and serve as chair of the scientific Protocol Review Committee. Nationally, I sit on the editorial board for multiple peer-reviewed oncology journals, am a member of NCI’s Pancreatic Cancer Task Force and the NCCN Pancreatic Cancer guidelines committee. http://cancer.ucsf.edu/people/profiles/ko_andrew.3444 *UCSF authors in bold 10
Presentations CRS-207 immunotherapy expressing mesothelin, combined with chemotherapy as treatment for malignant pleural mesothelioma (MPM). Authors*: Raffit Hassan, Evan W. Alley, Hedy L. Kindler, Scott Joseph Antonia, Thierry Marie Jahan, Somayeh Honarmand, Katherine McDougall, Chan C. Whiting, Nitya Nair, Amanda Enstrom, Ed Lemmens, Takahiro Tsujikawa, Sushil Kumar, Lisa M Coussens, Aimee Murphy, Anish Thomas, Dirk G. Brockstedt Abstract #: 8558 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #186 Session: Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers Citation: J Clin Oncol 34, 2016 (suppl; abstr 8558) __________________________________________________________________________ Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C. Authors*: Shirish M. Gadgeel, James Stevenson, Corey J. Langer, Leena Gandhi, Hossein Borghaei, Amita Patnaik, Liza Cosca Villaruz, Matthew A. Gubens, Ralph J. Hauke, James Chih-Hsin Yang, Lecia V. Sequist, Robert D. Bachman, Joy Yang Ge, Harry Raftopoulos, Vassiliki Papadimitrakopoulou Abstract #: 9016 Presentation Date/Time: Saturday, June 4: 8:00 - 11:30 AM Location: Hall A, Poster Board #339 Session: Lung Cancer - Non-Small Cell Metastatic Citation: J Clin Oncol 34, 2016 (suppl; abstr 9016) Gubens Research Interests: Matthew Gubens is a thoracic oncologist who treats patients with lung cancer, mesothelioma and other thoracic malignancies, including thymoma and thymic carcinoma, which are rare tumors of the mediastinum. His research involves designing clinical trials to study new compounds and treatment strategies in lung cancer. He and his colleagues have a special interest in translational medicine, and are actively working to translate laboratory-based findings to the clinic, especially for patients with epidermal growth factor receptor (EGFR) mutations. The group is also active in trials evaluating new immunotherapy approaches in thoracic malignancies. Dr. Gubens is a member of the American Society of Clinical Oncology, the International Association for the Study of Lung Cancer and the International Thymic Malignancy Interest Group. http://profiles.ucsf.edu/matthew.gubens *UCSF authors in bold 11
Page 1 and 2: UCSF HELEN DILLER FAMILY COMPREHENS
Page 3 and 4: HDFCCC Overview A Designated NCI Co
Page 5 and 6: HDFCCC Overview Core Capabilities S
Page 7 and 8: Presentations Presentations View fu
Page 9: Presentations Phase II trials of ce
Page 13 and 14: Presentations Long-term OS for pati
Page 15 and 16: Presentations Randomized phase 2 st
Page 17 and 18: Presentations Genomic Profiling to
Page 19 and 20: Presentations Validating RNAseq-sig
Page 21 and 22: Presentations Phase I/II study of V
Page 23 and 24: Presentations Clinical and genomic
Page 25 and 26: Presentations IMAAGEN trial safety
Page 27 and 28: Presentations Immunogenicity of sip
Page 29 and 30: Presentations Pembrolizumab for adv
Page 31 and 32: Presentations Novel T cell exhausti
Page 33 and 34: Presentations Correlation between m
Page 35 and 36: Presentations ATLAS: A randomized,
Page 37 and 38: Presentations A prospective analysi
Page 39 and 40: Presentations Circulating Biomarker
Page 41 and 42: Presentations Extended follow-up re
Page 43 and 44: Presentations Adjuvant temozolomide
Page 45 and 46: Presentations Ribociclib (LEE011) a
Page 47 and 48: Presentations Androgen receptor (AR
Page 49 and 50: Presentations Efficacy and hematolo
Page 51 and 52: Presentations IMpassion130: a Phase
Page 53 and 54: Presentations Randomized phase II t
Page 55 and 56: Presentations Phase II trial with t
Page 57 and 58: Presentations Academic and Communit
Page 59 and 60: Presentations Prevention of everoli
Page 61 and 62:
Presentations A phase 2 randomized,
Page 63 and 64:
Presentations PD-L1 expression, Can
Page 65 and 66:
Presentations The Heart of the Matt
Page 67 and 68:
Presentations 4-year results of the
Page 69 and 70:
Presentations Impact of landmark re
Page 71 and 72:
Presentations Phase II study of ali
Page 73 and 74:
Presentations Can lay health worker
Page 75 and 76:
Presentations Medical Management of
Page 77 and 78:
Presentations Prospective evaluatio
Page 79 and 80:
Presentations A phase II randomized
Page 81 and 82:
Presentations Early, molecular dete
Page 83 and 84:
Presentations Metastatic melanoma,
Page 85 and 86:
Presentations Three-year overall su
Page 87 and 88:
Presentations Heritage: A phase III
Page 89 and 90:
Presentations Determining barriers
Page 91 and 92:
Presentations Controversies in Loca
Page 93 and 94:
Presentations A pharmacodynamic stu
Page 95 and 96:
Presentations Final results of a ph
Page 97 and 98:
Presentations Comparative performan
Page 99 and 100:
Presentations Identification of sym
show all

UCSF HELEN DILLER FAMILY COMPREHENSIVE CANCER CENTER

Create successful ePaper yourself

Delete template?

Save as template?